Evidence map›Paper›PMID 35037618›Full record

ReviewDeutsches Arzteblatt international2022

Extracorporeal Membrane Oxygenation.

Alexander M Bernhardt, Benedikt Schrage, Ines Schroeder, Georg Trummer, Dirk Westermann, Hermann Reichenspurner

Open access · greenAbstract readReview
In one paragraph

Review in Deutsches Arzteblatt international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. National Heart Center Perfusion Guidelines.Saudi medical journal · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Incidence of neutrophil extracellular traps (NETs) in different membrane oxygenators: pilot in vitro experiments in commercially available coated membranes.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025
    Article
  9. Article
  10. Research progress on the pathogenesis of AKI complicated by ECMO.Clinical and experimental nephrology · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. In Reply.Deutsches Arzteblatt international · 2022
    Article
  17. Implantation Strategies and ECMO Interhospital Transports.Deutsches Arzteblatt international · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alexander M BernhardtDepartment for Cardiovascular Surgery, University Heart & Vascular Center Hamburg; Department of Cardiology, University Heart & Vascular Center Hamburg; Department of Anaesthesiology, LMU Hospital Munich; Department of Cardiovascular Surgery, Heart Center, Faculty of Medicine, University of Freiburg.
Benedikt Schrage
Ines Schroeder
Georg Trummer
Dirk Westermann
Hermann Reichenspurner
Deutsches Herzzentrum München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVeno-venous extracorporeal membrane oxygenation (VV-ECMO) and veno-arterial extracorporeal membrane oxygenation (VA-ECMO), also known as extracorporeal life support (ECLS), can both be used to treat patients with acute pulmonary or cardiovascular failure.

methodsThis review is based on publications retrieved by a selective search in PubMed on the topics of cardiogenic shock and acute pulmonary failure, also known as the acute respiratory distress syndrome (ARDS), as well as on ECMO. Attention was given chiefly to randomized, controlled trials and guidelines.

resultsInitial findings from prospective, randomized trials of VV-ECMO are now available. Trials of ECLS therapy are now in progress or planned. A meta-analysis of two randomized, controlled trials of VV-ECMO for ARDS revealed more frequent survival 90 days after randomization among patients treated with VV-ECMO, compared to the control groups (36% vs. 48%; RR = 0.75 [95% confidence interval 0.6; 0.94]). For selected patients, after evaluation of the benefit-risk profile, VV-ECMO is a good treatment method for severe pulmonary failure, and ECLS for cardiogenic shock and resuscitation. The goal is to secure the circulation so that native heart function can be stabilized in the patient's further course or a permanent left-heart support system can be implanted, or else to support lung function until recovery.

conclusionECMO is a valid option in selected patients when conservative treatment has failed.

Indexed as

Extracorporeal Membrane OxygenationRespiratory Distress SyndromeRespiratory InsufficiencyHumansProspective StudiesRetrospective StudiesShock, Cardiogenic

Identifiers

PMID35037618
PMCPMC9342119
OpenAlexW4206780339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.